Formycon Is Latest To Win EMA Endorsement For Aflibercept

Positive Opinions Issued After Dual Filings For Biosimilar Rival To Eylea

 
• By Dave Wallace

Dual filings for Formycon’s aflibercept biosimilar have delivered results, with the Eylea rival endorsed under two names by the EMA’s CHMP.

Another Eylea biosimilar has made the grade in the EU (Shutterstock)

More from Biosimilars

More from Generics Bulletin